Abstract: Disclosed are a pyrimidine five-membered nitrogen heterocyclic derivative, a preparation method thereof and the pharmaceutical use thereof. Specifically disclosed are a pyrimidine five-membered nitrogen heterocyclic derivative represented by general formula (II), a preparation method thereof, a composition containing the derivative, and the use thereof as an SHP2 inhibitor and in the preparation of a medicament for preventing and/or treating tumors or cancer.

Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

Abstract: Methods, systems, and software are provided for validating a somatic sequence variant in a subject having a cancer condition. Sequence reads are obtained from sequencing cell-free DNA fragments in a liquid biopsy sample of the subject. Sequence reads are aligned to a reference sequence. A variant allele fragment count and locus fragment count are identified for a candidate variant that maps to a locus in the reference sequence. The variant allele fragment count is compared against a dynamic variant count threshold for the locus. The threshold is based on a pre-test odds of a positive variant call for the locus, based on the prevalence of variants in a genomic region including the locus in a cohort of subjects having the cancer condition. The somatic sequence variant in the subject is validated, or rejected, when the variant allele fragment count for the candidate variant satisfies, or does not satisfy, the threshold.

Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention discloses a method of hot recycling repairing by optimizing a proportion of an asphalt mixture on a pavement alignment variation section. According to the method of the present invention, by regulating and optimizing the proportion of a recycled asphalt mixture, internal frictional resistance and cohesion of the recycled asphalt mixture are improved, elastic modulus and shear strength of the recycled asphalt mixture are increased, overall bearing capacity of an asphalt pavement is improved, and diseases such as tracks caused by vehicle loads are effectively resisted. The pavement asphalt mixture is made to adapt to and be enough to bear additional loads increased manifold without generating early defects and road diseases. Therefore, the overall service life of a road is further prolonged.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, n and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Methods, systems, and software are provided for validating a copy number variation in a test subject. A first dataset is obtained comprising bin-level sequence ratios, segment-level sequence ratios and segment-level measures of dispersion. Bins representing regions of a human reference genome are determined from sequencing cell-free nucleic acids in a liquid biopsy sample and reference samples. Segments encompass subsets of adjacent bins, where segment-level sequence ratios and measures of dispersion are determined using bin-level sequence ratios. A copy number status annotation for a segment is validated by applying the first dataset to a plurality of filters comprising a measure of central tendency bin-level sequence ratio filter, a confidence filter, and a measure of central tendency-plus-deviation bin-level sequence ratio filter. When a filter is fired, the copy number status annotation of the segment is rejected; and when no filter is fired, the copy number status annotation of the segment is validated.

Abstract: A method for processing account information in a block chain is provided. A computer device receives identity information and a transfer request, the transfer request requesting to transfer a resource in an account to a target account, the target account being generated by a certificate center. The computer device obtains owner information of the account from the certificate center according to the transfer request. The computer device compares the identity information and the owner information. The computer device transmits an authentication request to the block chain in response to determining that the identity information and the owner information are consistent, the authentication request requesting the block chain to transfer the resource in the account to the target account.

Abstract: Methods, systems, and software are provided for validating a somatic sequence variant in a subject having a cancer condition. Sequence reads are obtained from sequencing cell-free DNA fragments in a liquid biopsy sample of the subject. Sequence reads are aligned to a reference sequence. A variant allele fragment count and locus fragment count are identified for a candidate variant that maps to a locus in the reference sequence. The variant allele fragment count is compared against a dynamic variant count threshold for the locus. The threshold is based on a pre-test odds of a positive variant call for the locus, based on the prevalence of variants in a genomic region including the locus in a cohort of subjects having the cancer condition. The somatic sequence variant in the subject is validated, or rejected, when the variant allele fragment count for the candidate variant satisfies, or does not satisfy, the threshold.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: Methods, systems, and software are provided for estimating a circulating tumor fraction for a test subject. Sequence reads are obtained from a panel-enriched sequencing reaction, including sequences for a first plurality of cfDNA fragments corresponding to probe sequences and a second plurality of cfDNA fragments not corresponding to probe sequences. Bin-level coverage ratios are determined from the sequences. Segments are formed by grouping adjacent bins based on similar coverage ratios and segment-level coverage ratios are determined based on bin-level coverage ratios for bins in the segment. For each simulated circulating tumor fraction in a plurality of circulating tumor fractions, segments are fitted to an integer copy state by identifying the integer copy state that best matches the segment-level coverage ratio.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: Sterilization indicators include a first substrate and a second substrate. The first substrate has a compartment containing a fusible indicator material, and a channel in contact with the compartment for the molten indicator material to flow, and a wicking material in contact with the channel. The second substrate has a transparent segment aligned to overlay the wicking material. A high temperature sealing pressure sensitive adhesive layer adheres the first substrate to the second substrate. The adhesive layer includes a (meth)acrylate-based pressure sensitive adhesive matrix and a high temperature sealing agent. The high temperature sealing agent is essentially unreactive at ambient temperature but upon exposure to elevated temperatures forms a heat-sealed adhesive bond.

Abstract: A pharmaceutical composition containing nitroxoline for the treatment of bladder cancer, a nitroxoline oral solid tablet, a preparation method therefor and use thereof. The pharmaceutical composition comprises nitroxoline, a filler, a disintegrating agent, a binder, and a lubricant. The lubricant is selected from one or two of sodium dodecyl sulfate and sodium stearyl fumarate. The pharmaceutical composition has a moderate dissolution rate, can avoid the burst release phenomenon, is moisture-proof and impermeable, has good stability, is secure and effective, is convenient to take, has strong patient compliance, and meets the requirements of being an oral solid tablet. The preparation method has stable production process, good reproducibility, easy mass production, and good clinical use value and social benefits.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: A pulse hydrogen supply system for a proton exchange membrane fuel cell is provided. The system comprises a fuel cell, a high-pressure hydrogen bottle, a first pressure relief valve, an ejector, a steam-water separator, a first pressure control valve, a first pressure sensor, a high-pressure vessel, a first electromagnetic valve, a low-pressure vessel, a diaphragm pump, and a second electromagnetic valve. The high-pressure hydrogen bottle, the first pressure relief valve, the first pressure control valve, the ejector and the first pressure sensor are sequentially arranged on a gas inlet pipeline; the high-pressure vessel and the first electromagnetic valve are sequentially arranged on a branch pipeline; the second electromagnetic valve, the low-pressure vessel and the diaphragm pump are sequentially arranged on a first output loop; and the first output pipeline and the gas inlet pipeline form a loop.

Abstract: A data temporary storage apparatus includes a moving unit coupled to a first storage unit and multiple second storage units. The moving unit receives a moving instruction having contents including a read address, a destination address and a predetermined moving rule. The moving unit further executes the moving instruction to fetch input data by row from the first storage unit according to the read address, and to temporarily stores one after another in an alternate and sequential manner the data in each row to each of the second storage units indicated by the destination address. The data moving, data reading and convolution approaches of the present invention implement in parallel data moving and a convolution operation, achieving a ping-pong operation of convolution units and enhancing convolution efficiency, while reducing memory costs since configuring two data storage spaces in a memory is not necessary.

Abstract: An alloy cast strip preparation method includes a melting process and a casting cooling process. The melting process includes controlling a power of an induction melting furnace to perform a cyclic heat treatment to completely melt an alloy raw material before a surface temperature of a melt obtained by melting the alloy raw material is raised to 1300° C., and, after the alloy raw material is melted, adjusting the power of the induction melting furnace to stabilize the surface temperature of the melt at a temperature in a range from 1400° C. to 1500° C. The casting cooling process includes performing casting cooling on the melt arranged on a surface of a rotary cooling roll to obtain an alloy cast strip while controlling a surface linear velocity of the rotary cooling roll to be from 1.5 m/s to 2.25 m/s.

Abstract: The present application relates to biocompatible polymers that exhibit a shape-memory effect, devices made using the materials and methods of producing such materials and devices.